CHF-6366
- Generic Name
- CHF-6366
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366
Phase 1
Completed
- Conditions
- AsthmaChronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 118
- Registration Number
- NCT03378648
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath